Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Avkjølte blodplateundersøkelse "CHIPS" (CHIPS)

23. oktober 2026 oppdatert av: Philip Spinella

Studie av avkjølte blodplater

A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

1000

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Western Australia
      • Murdoch, Western Australia, Australia, 6150
        • Fiona Stanley Hospital
      • Nedlands, Western Australia, Australia, 6009
        • Sir Charles Gairdner Hospital
    • Arizona
      • Pheonix, Arizona, Forente stater, 85054
        • Mayo Clinic Arizona
      • Tuscon, Arizona, Forente stater, 85713
        • Banner University Medical Center
    • California
      • Los Angeles, California, Forente stater, 90095
        • Ronald Reagan UCLA Medical Center
    • Florida
      • Gainesville, Florida, Forente stater, 32608
        • University of Florida
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Northwestern Memorial Hospital
      • Maywood, Illinois, Forente stater, 60153
        • Loyola Universtiy Medical Center
    • Kansas
      • Kansas City, Kansas, Forente stater, 66103
        • University of Kansas Medical Center
    • Kentucky
      • Lexington, Kentucky, Forente stater, 40536
        • University of Kentucky
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • John Hopkins
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • University of Michigan
    • Minnesota
      • Minneapolis, Minnesota, Forente stater, 55455
        • University of Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Mayo Clinic
    • North Carolina
      • Winston-Salem, North Carolina, Forente stater, 27157
        • Wake Forest
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45229
        • Cincinnati Children's Hospital
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Oregon Health and Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • University of Pittsburgh Medical Center
    • Rhode Island
      • Providence, Rhode Island, Forente stater, 02910
        • Rhode Island Hospital
    • Texas
      • Dallas, Texas, Forente stater, 75235
        • University of Texas Children's Medical Center
      • Dallas, Texas, Forente stater, 75235
        • University of Texas Medical Center Clements
      • Houston, Texas, Forente stater, 77030
        • Memorial Hermann Texas Medical Center
      • Houston, Texas, Forente stater, 77030
        • Baylor Texas Children's
    • Wisconsin
      • Madison, Wisconsin, Forente stater, 53792
        • University of Wisconsin- Madison
      • Milwaukee, Wisconsin, Forente stater, 53226
        • Children's Hospital of Wisconsin
      • Milwaukee, Wisconsin, Forente stater, 53215
        • Aurora St. Luke's Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 sekund til 84 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Viable neonates ≥ 3 kg at time of enrollment (as defined in Section 4.1) OR age greater than 28 days and less than 85 years of age at time of consent; AND
  • Planned complex cardiac surgery with planned use of cardiopulmonary bypass, with an expectation of bleeding requiring platelet transfusion.

Exclusion Criteria:

  • Expected order for washed or volume reduced platelets
  • Patient with known anti-platelet antibodies
  • Platelet transfusion refractoriness due to anti-HLA antibodies
  • Known or suspected pregnancy
  • Previously randomized in this study
  • Conscious objection or unwillingness to receive blood products
  • Known IgA deficiency
  • Known congenital platelet disorder
  • Known congenital bleeding disorder
  • Planned post-operative extracorporeal membrane oxygenation (ECMO), ventricular assist device (VAD), and/or continuous renal replacement therapy (CRRT)/ hemodialysis
  • Patients intended to receive whole blood either intra-operative or post-operative for bleeding
  • Platelet transfusion (of any type) within 24 hours prior to the date of surgery
  • Pre-operative thrombocytopenia, defined as platelet count <75x10(9)/L, based on the most recent labs completed within 72 hours prior to the date of surgery.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Room Temperature Platelets

Platelets stored at 20-24 degrees Celsius

Platelets stored at 20-24 degrees Celsius

Eksperimentell: Cold Stored Platelets

Platelets stored at 1-6 degree Celsius

Platelets stored at 1-6 degree Celsius

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hemostatic Efficacy
Tidsramme: 24 hours after first study platelet transfusion

Assessed by a bleeding score, a modified Peri-Operative bleeding score: the score ranges from 1-5. A lower score signifies a better outcome.

24 hours after first study platelet transfusion

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Chest Tube Output Through 24 Hours
Tidsramme: 24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)

Chest tube output will be assessed by volume

24 hours from first study platelet transfusion or ICU admit (determined from which occurs last)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Blood Product Administration
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion

The quantity of RBCs, Plasma, Platelets, Cryoprecipitate, and Whole blood

24 and 72 hours from start time of first study platelet transfusion
Transfusion Associated Adverse Events
Tidsramme: within 7 days of first study platelet transfusion

As per CDC guidelines for transfusion associated adverse events

within 7 days of first study platelet transfusion
Arterial Thrombotic Event
Tidsramme: within 7 days of first study platelet transfusion

Stroke, MI, aortic thromboic even

within 7 days of first study platelet transfusion
Venous Thrombotic Event
Tidsramme: within 7 days of first study platelet transfusion

Deep vein thrombosis or pulmonary embolism confirmed by ultrasound, venography, perfusion scan, spiral CT, MRI, or pulmonary angiogram

within 7 days of first study platelet transfusion
All Cause Mortality
Tidsramme: up to 28 days

Death for any reason

up to 28 days
Total Dose of Individual Hemostatic Adjuncts (Units/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (mcg/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (mg/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

24 and 72 hours from start time of first study platelet transfusion
Total Dose of Individual Hemostatic Adjuncts (Grams/kg)
Tidsramme: 24 and 72 hours from start time of first study platelet transfusion

Antifibrinolytic and coagulation factor concentrates

Epsilon-amino-caproic acid

24 and 72 hours from start time of first study platelet transfusion
Mechanical Ventilation
Tidsramme: up to 28 days after first study platelet transfusion

Number of participants with need for mechanical ventilation

up to 28 days after first study platelet transfusion
Length of Stay
Tidsramme: up to 28 days

ICU and hospital length of stay

up to 28 days
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hemoglobin
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours - Hematocrit
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement).

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Platelet Count
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- INR
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- PTT
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Relative Change in Hemostatic Parameters at 6 and 24 Hours- Fibrinogen
Tidsramme: 6 and 24 hours after first study platelet transfusion

Relative change = (post transfusion measurement - pre transfusion measurement)/(pre transfusion measurement)

6 and 24 hours after first study platelet transfusion
Unplanned Sternal Closure Delay
Tidsramme: prior to ICU admission

Sternum left open after cardiac surgery

prior to ICU admission
Re-exploration for Bleeding
Tidsramme: 24 hours first study platelet transfusion

Return to OR after ICU admission

24 hours first study platelet transfusion
Unplanned Extracorporeal Support Post Operatively
Tidsramme: within 48 hours of first study platelet transfusion

Unplanned placement on ECMO post operatively within 48 hours of 1st transfusion

within 48 hours of first study platelet transfusion
Morbidities After ICU Admission
Tidsramme: within 7 days of first study platelet transfusion

Acute respiratory distress syndrome, need for and duration of renal support, renal failure, septic shock

within 7 days of first study platelet transfusion
Measures of End Organ Injury- BUN and Creatinine
Tidsramme: within 48 hours of first study platelet transfusion worst value

If BUN, creatinine are collected clinically.- worst value

within 48 hours of first study platelet transfusion worst value
Measures of End Organ Injury- Lactate
Tidsramme: within 48 hours of first study platelet transfusion worst value

If lactate was collected clinically. Worst value

within 48 hours of first study platelet transfusion worst value
Measures of End Organ Injury- Troponin
Tidsramme: within 48 hours of first study platelet transfusion.

If lactate was collected clinically. Worst value

within 48 hours of first study platelet transfusion.
Measures of End Organ Injury- ALT and AST
Tidsramme: within 48 hours of first study platelet transfusion.

If lactate was collected clinically. Worst value

within 48 hours of first study platelet transfusion.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Philip C Spinella, MD, University of Pittsburgh
  • Studieleder: Marie E Steiner, MD, University of Minnesota
  • Studieleder: Nicole D Zantek, MD, University of Minnesota

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

21. oktober 2021

Primær fullføring (Faktiske)

25. mars 2025

Studiet fullført (Faktiske)

21. april 2025

Datoer for studieregistrering

Først innsendt

31. mars 2021

Først innsendt som oppfylte QC-kriteriene

2. april 2021

Først lagt ut (Faktiske)

8. april 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

23. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • CHIPS
  • W81XWH2090021 (Annet stipend/finansieringsnummer: DoD)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere